Matthew Teltser: Final Debarment Order
Published Date: 2/6/2026
Notice
Summary
Matthew Teltser is permanently banned from working with any company that has drug products approved or waiting for approval because he was convicted of a serious crime related to drug development. He didn’t respond to the FDA’s notice, so the ban started on February 6, 2026. He can apply to end this ban anytime, but it won’t be easy or quick.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 3 costs, 1 mixed.
Civil Penalties for Employers Who Hire Debarred Person
Any person with an approved or pending drug product application who knowingly employs, retains as a consultant or contractor, or otherwise uses the services of Matthew Teltser during his period of debarment will be subject to civil money penalties under section 307(a)(6) of the FD&C Act. The debarment period began February 6, 2026.
Individual Penalties for Providing Services During Debarment
If Matthew Teltser provides services in any capacity to a person with an approved or pending drug product application during his debarment, he will be subject to civil money penalties under section 307(a)(7) of the FD&C Act. The debarment is effective February 6, 2026.
FDA Will Not Accept ANDAs From Debarred Individual
During his period of debarment, FDA will not accept or review any abbreviated new drug application (ANDA) from Matthew Teltser, except in connection with an audit under section 306 of the FD&C Act. This restriction began on February 6, 2026.
Permanent FDA Debarment Effective Feb 6, 2026
The FDA permanently debarred Matthew Teltser from providing services in any capacity to a person that has an approved or pending drug product application, effective February 6, 2026. The debarment follows his June 10, 2025 federal conviction for making a false statement and his failure to request a hearing after receiving FDA's notice on September 8, 2025.
Right to Apply for Special Termination; Public Filing Rules
Dr. Teltser may apply at any time for special termination of debarment under section 306(d)(4) of the FD&C Act. Applications submitted electronically to https://www.regulations.gov will be posted publicly unless submitted as a written/paper confidential submission following FDA's instructions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-02348 — Procurement List; Additions and Deletions
Starting March 8, 2026, some services will be added to the government’s special shopping list, meaning nonprofit groups that help people who are blind or severely disabled will get new contracts. At the same time, a few products will be removed from that list. These changes help support great causes without adding extra costs or paperwork for small businesses.
Next: 2026-02351 — Agency Information Collection Activities; Extension; International Mail Duty Worksheet (IMDW)
U.S. Customs and Border Protection is extending the use of the International Mail Duty Worksheet (IMDW), which helps track duties on international mail. This extension means businesses and mail handlers will keep using the same form, with no new costs or changes. You’ve got until March 9, 2026, to share your thoughts or questions about this paperwork.